Stock comparison
Haemonetics
Zoetis
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
ZTS
Zoetis
Market cap
$34.09B
Sector
Healthcare
Overall winner
Zoetis ZTS
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | ZTS | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 64C | HAE |
| Benjamin Graham | 85A | 70B | HAE |
| Philip Fisher | 60C | 61C | ZTS |
| Peter Lynch | 54C | 42D | HAE |
| Joel Greenblatt | 31F | 43D | ZTS |
| Charlie Munger | 54D | 69B | ZTS |
| Terry Smith | 55D | 73B | ZTS |
Side-by-side metrics
| Metric | HAE | ZTS |
|---|---|---|
| Market cap | $2.98B | $34.09B |
| P/E (TTM) | 24.8x | 11.9x |
| EV/EBIT | 14.1x | 10.8x |
| ROIC (TTM) | 8.37% | 21.79% |
| Gross margin | 55.74% | 70.75% |
| Net margin | 7.29% | 27.79% |
| Revenue CAGR 5y | 7.65% | 5.04% |
| EPS CAGR 5y | 24.62% | 8.88% |
| Debt / Equity | 1.5x | 0.1x |
| Dividend yield | 0.0% | 2.77% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EPS CAGR 5y24.62%vs 8.88%+64%
- Revenue CAGR 5y7.65%vs 5.04%+34%
ZTS leads on
- Dividend yield2.77%vs 0.0%+100%
- Debt / Equity0.1xvs 1.5x+96%
- Market cap$34.09Bvs $2.98B+91%
- Net margin27.79%vs 7.29%+74%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.